 |
 |
|
 |
 |
Ventana Biotech inc strategy |
 Ventana Biotech Inc strives to improve the health and quality of life for patients, develop breakthrough treatment options for physicians, offer rewarding careers to employees, and deliver value to our shareholders. Our strategy is to build on anticipated success of what will be our flagship product and continue to invest in new targets as well as R&D in obesity to provide longer-term growth.
Ventana has evolved to become a scientifically strong early stage biotech company that is focused on disease areas that impact 1 in 5 people in the world. Our team is dedicated to the discovery and development of targeted therapies to revolutionize the way obesity is treated and improve treatment outcomes.
Our obesity team is dedicated to the discovery and development of novel drugs for the treatment of type 2 diabetes and obesity. The strategy for this business team is to advance a pipeline of innovative diabetes and obesity research projects through clinical proof-of-concept studies, with a view to then potentially seeking financially attractive development and commercialization partnerships for these research programs.
Our goal is to pave the way for the future of diabetes and obesity treatments. We believe that our Company strategy is poised to deliver a rich pipeline of promising drug candidates that have the potential to significantly improve the treatment options available to patients today. |
|
|
|
 |
 |
|
 |
|
|
 |
